Overview
Nicotinamide adenine dinucleotide (NAD⁺) is the central dinucleotide coenzyme of all living cells, combining two roles: a hydride-ion carrier in hundreds of redox reactions and a consumable substrate that signalling enzymes cleave irreversibly. In its oxidised form (NAD⁺) the molecule accepts electrons; in its reduced form (NADH) it donates them, driving the flux of energy from substrate catabolism to the respiratory chain. In parallel, NAD⁺ is consumed by sirtuins, PARPs and CD38, which release nicotinamide and use the ADP-ribose moiety for post-translational protein modification and intracellular signalling [1][2]. Because of this dual role, the intracellular NAD⁺ level couples the metabolic state of the cell to gene expression, DNA repair and calcium signalling, and the age-associated decline of this pool has made NAD⁺ a key object of ageing-biology research [1].
Structure and physicochemistry
The NAD⁺ molecule consists of two nucleotides joined by a pyrophosphate bridge: one bears adenine, the other nicotinamide, each attached to a ribose [3]. The free-acid molecular formula is C₂₁H₂₇N₇O₁₄P₂, with a molar mass of ≈ 663.43 g/mol. The positive charge on the quaternary nitrogen of the nicotinamide pyridinium ring is what the “plus” in NAD⁺ denotes; the compound is a zwitterion. The reactive centre of redox chemistry is C4 of the nicotinamide ring. In the phosphorylated derivative NADP⁺, an additional phosphate esterifies the 2′-OH of the adenosine ribose; this seemingly minor difference channels NADP(H) mainly into anabolic and antioxidant reactions, whereas NAD(H) serves catabolism [4]. NAD⁺ is highly water-soluble, hygroscopic, and absorbs ultraviolet light around 260 nm owing to its adenine.
Biosynthetic pathways
Cells synthesise and replenish NAD⁺ through three converging routes [3][5]. De novo synthesis begins with the amino acid tryptophan, which the kynurenine pathway converts to quinolinic acid and then to nicotinate mononucleotide (NAMN). The Preiss-Handler pathway uses nicotinic acid (vitamin B₃): NAPRT forms NAMN, NMN adenylyltransferase (NMNAT) adds the adenylyl moiety to give NAAD, and NAD synthetase (NADSYN1) amidates it to NAD⁺. Most active in mammals is the salvage pathway: nicotinamide (NAM), released by NAD⁺-consuming enzymes, is converted by nicotinamide phosphoribosyltransferase (NAMPT) to NMN, the rate-limiting step of the whole cycle. Three NMNAT isoforms complete synthesis in different compartments: NMNAT1 in the nucleus, NMNAT2 in the cytosol and Golgi, NMNAT3 in mitochondria. A separate entry point is nicotinamide riboside (NR): the kinases NRK1/2 phosphorylate it to NMN, a discovery that established a Preiss-Handler-independent route to NAD⁺ in fungi and humans [5].
Redox biochemistry
Functionally, NAD⁺ is a carrier of two reducing equivalents. In dehydrogenase reactions (glycolysis, the Krebs cycle, β-oxidation), C4 of the nicotinamide ring accepts a hydride ion (H⁻, i.e. two electrons and one proton) to become NADH, while the second proton is released into solution [6]. The standard redox potential of the NAD⁺/NADH couple is about −0.32 V, which makes NADH a convenient electron donor for complex I of the respiratory chain. A key analytical property: the reduced form NADH has a characteristic absorption band at 340 nm (molar coefficient ε ≈ 6220 M⁻¹·cm⁻¹) and is fluorescent, whereas oxidised NAD⁺ does not absorb at 340 nm. Most enzymatic assays are built on this difference. The free cytosolic NAD⁺/NADH ratio is kept high (an oxidising milieu), whereas the NADP⁺/NADPH couple is shifted toward the reduced form, providing reducing power for biosynthesis and antioxidant defence [4][6].
NAD⁺-consuming enzymes and signalling
Beyond its reversible redox role, NAD⁺ is a consumable substrate for three enzyme families that cleave the glycosidic bond between nicotinamide and ADP-ribose [4]. Sirtuins (SIRT1–7) are NAD⁺-dependent deacylases that remove acyl groups from protein lysines, producing nicotinamide and 2′-O-acyl-ADP-ribose; their activity depends directly on NAD⁺ availability, so they “read” the energetic state of the cell and regulate metabolism, stress resistance and transcription [7]. Poly(ADP-ribose) polymerases (chiefly PARP1) consume NAD⁺ in response to DNA damage, building ADP-ribose polymers on target proteins. The glycohydrolases CD38 and CD157 convert NAD⁺ into cyclic ADP-ribose and NAADP, second messengers that release Ca²⁺. All of these reactions liberate nicotinamide, which re-enters the salvage cycle, so the signalling “consumption” and biosynthetic “replenishment” of NAD⁺ form a single dynamic turnover. CD38 is one of the principal consumers and has been shown to dictate the age-related decline of NAD⁺ [8][9].
Research in ageing and metabolism
Numerous studies in model organisms and tissues have shown that NAD⁺ concentration declines with age, and that this decline is accompanied by mitochondrial dysfunction [1]. In the work of Gomes and colleagues, falling NAD⁺ weakened SIRT1 activity, destabilised HIF-1α regulation and produced a “pseudohypoxic” state with impaired nuclear-mitochondrial communication that was reversible in mice upon restoration of the NAD⁺ pool [10]. Zhang and colleagues demonstrated that replenishing NAD⁺ through a precursor improved mitochondrial and stem-cell function and extended the lifespan of aged mice [11]. In parallel, the age-dependent accumulation and activation of CD38 was described as a mechanism of NAD⁺ depletion mediated through SIRT3 [8][9]. These observations turned NAD⁺ metabolism into an active field of ageing, metabolic and neurodegenerative research; importantly, this concerns preclinical and mechanistic data, not clinical recommendations [2].
Analytical characterisation
The identity and purity of NAD⁺ as a reagent are confirmed chiefly by high-performance liquid chromatography (HPLC/UPLC) with spectrophotometric detection at 260 nm; the quantitative NAD-metabolome profile (NAD⁺, NADH, NMN, NAM, NADP) is measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Classical enzymatic “cycling” assays measure the sum of NAD⁺/NADH through coupled dehydrogenase reactions via absorbance at 340 nm. Structure is confirmed by NMR spectroscopy (in particular ³¹P NMR for the pyrophosphate bridge) and high-resolution mass spectrometry. The A₂₆₀/A₃₄₀ absorbance ratio (and the absence of a 340 nm band) serves as a quick indicator that the material is in the oxidised form and carries no significant NADH impurity.
Handling/reconstitution chemistry and storage
As a reagent, NAD⁺ is usually supplied as a lyophilised powder or as the disodium salt (hydrate); the substance is hygroscopic, so it is most stable as a dry solid at −20 °C in a tightly closed, moisture-protected container. The chemical stability of the two forms is mirror-image: oxidised NAD⁺ is relatively stable in mildly acidic media but degrades rapidly under alkaline conditions (hydrolysis of the nicotinamide-ribose glycosidic bond), whereas reduced NADH is conversely labile in acid and more stable in base. Working solutions are therefore prepared in water or a neutral-pH buffer, used fresh, aliquoted and stored frozen, avoiding repeated freeze-thaw cycles. All handling is strictly for research use only (RUO) and does not involve any administration to humans.
Related molecules (NMN, NR, NADH)
NAD⁺ belongs to the pyridine dinucleotide family and is biosynthetically linked to a series of precursors and derivatives [12]. NADH is its reduced form; NADP⁺/NADPH are the phosphorylated analogues used in anabolism. The direct metabolic precursors are nicotinamide mononucleotide (NMN), which NMNAT converts straight to NAD⁺, and nicotinamide riboside (NR), which enters the pool at the NMN level via the NRK kinases. The “vitamin” precursors are nicotinamide (NAM) and nicotinic acid (NA) are forms of vitamin B₃. In ageing-biology research it is precisely these precursors (NMN, NR) that are studied as tools for experimentally raising intracellular NAD⁺, which makes them a natural context for a monograph on the coenzyme itself [12].